Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Stopped early · Phase 2

Conditions studied: Kidney Transplant Recipients

In brief

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Key facts

Study ID

NCT01517984

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

52

Starts

2010-11-01

Expected to finish

2015-05-01

Last updated by the study team

2017-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California Los Angeles — Los Angeles, California, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• University of Michigan Hospital — Ann Arbor, Michigan, United States
• Washington University — St Louis, Missouri, United States
• Mount Sinai School of Medicine — New York, New York, United States
• University Hospitals of Cleveland — Cleveland, Ohio, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• The Methodist Hospital — Houston, Texas, United States
• Health Sciences Centre — Winnipeg, Manitoba, Canada
• Toronto General Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.